company background image
ARVN

Arvinas NasdaqGS:ARVN Stock Report

Last Price

US$54.46

Market Cap

US$2.9b

7D

-1.8%

1Y

-40.3%

Updated

14 Aug, 2022

Data

Company Financials +
ARVN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ARVN Stock Overview

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.

Arvinas, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Arvinas
Historical stock prices
Current Share PriceUS$54.46
52 Week HighUS$98.67
52 Week LowUS$34.90
Beta2
1 Month Change9.25%
3 Month Change28.29%
1 Year Change-40.29%
3 Year Change127.96%
5 Year Changen/a
Change since IPO239.32%

Recent News & Updates

May 23

Arvinas: Still Holding, Just Not Buying More

Arvinas announced decent data from ARV-110 in February. The market may have expected more. I will continue to hold.

Shareholder Returns

ARVNUS PharmaceuticalsUS Market
7D-1.8%1.0%3.2%
1Y-40.3%1.3%-10.2%

Return vs Industry: ARVN underperformed the US Pharmaceuticals industry which returned 1.3% over the past year.

Return vs Market: ARVN underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is ARVN's price volatile compared to industry and market?
ARVN volatility
ARVN Average Weekly Movement10.0%
Pharmaceuticals Industry Average Movement12.1%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: ARVN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ARVN's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013280John Houstonhttps://www.arvinas.com

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG.

Arvinas, Inc. Fundamentals Summary

How do Arvinas's earnings and revenue compare to its market cap?
ARVN fundamental statistics
Market CapUS$2.90b
Earnings (TTM)-US$233.10m
Revenue (TTM)US$91.10m

31.8x

P/S Ratio

-12.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ARVN income statement (TTM)
RevenueUS$91.10m
Cost of RevenueUS$0
Gross ProfitUS$91.10m
Other ExpensesUS$324.20m
Earnings-US$233.10m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-4.38
Gross Margin100.00%
Net Profit Margin-255.87%
Debt/Equity Ratio0.1%

How did ARVN perform over the long term?

See historical performance and comparison